Market cap
$0 Mln
Recently Viewed
Clear AllMarket cap
$0 Mln
Revenue (TTM)
$2 Mln
P/E Ratio
--
P/B Ratio
9.2
Div. Yield
0 %
Today’s Range
52 Week Range
Liquidity
Net Profit (TTM)
$-54 Mln
ROE
-21.7 %
ROCE
-- %
Industry P/E
24.41
EV/EBITDA
0.4
Debt to Equity
0
Book Value
$--
EPS
$-0.6
Face value
--
Shares outstanding
119,080,000
CFO
$-487.94 Mln
EBITDA
$-571.08 Mln
Net Profit
$-596.36 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Humanigen (HGEN)
| -91.7 | 0.0 | -95.0 | -99.9 | -98.1 | -89.0 | -75.7 |
|
BSE Sensex*
| -8.7 | 2.7 | -5.2 | -2.4 | 8.6 | 9.8 | 11.5 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
2017
|
|---|---|---|---|---|---|---|---|
|
Humanigen (HGEN)
| -99.0 | -96.8 | -78.7 | 617.9 | -30.4 | 73.4 | -89.7 |
|
S&P Small-Cap 600
| 13.9 | -17.4 | 25.3 | 9.6 | 20.9 | -9.7 | 11.7 |
|
BSE Sensex
| 18.7 | 4.4 | 22.0 | 15.8 | 14.4 | 5.9 | 27.9 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Humanigen, Inc., a clinical-stage biopharmaceutical company, focuses on preventing and treating an immune hyper-response. The company is developing lenzilumab, an antibody that binds to and neutralizes granulocyte-macrophage colony-stimulating factor... (GM-CSF), to treat cytokine storm associated with COVID-19 for which it has completed a Phase 3 study and is the focus of a Phase 2/3 study sponsored by the NIH. It is also developing lenzilumab, which is associated with CD19-targeted CAR-T cell therapies, as well as exploring the effectiveness of lenzilumab in other inflammatory conditions, such as acute Graft versus Host Disease in patients undergoing allogeneic hematopoietic stem cell transplantation and in eosinophilic asthma, and rheumatoid arthritis. In addition, the company focuses on studying lenzilumab for patients with chronic myelomonocytic leukemia exhibiting RAS pathway mutations. Its pipeline also includes two other Humaneered monoclonal antibodies, ifabotuzumab, which binds to EphA3, and HGEN005, which targets EMR1, as well as treats a range of eosinophilic diseases, including eosinophilic leukemia as an optimized naked antibody and as the backbone for a novel CAR-T construct. Humanigen, Inc. was incorporated in 2000 and is headquartered in Short Hills, New Jersey. On January 3, 2024, Humanigen, Inc. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware. Read more
Chairman, CEO, Principal Financial & Accounting Officer
Dr. Cameron Durrant M.D., MBA
Chairman, CEO, Principal Financial & Accounting Officer
Dr. Cameron Durrant M.D., MBA
Headquarters
Short Hills, NJ
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of Humanigen Inc (HGEN) is $0.00 (NASDAQ) as of 07-Mar-2024 09:30 EDT. Humanigen Inc (HGEN) has given a return of -98.13% in the last 3 years.
Since, TTM earnings of Humanigen Inc (HGEN) is negative, P/E ratio is not available.
The P/B ratio of Humanigen Inc (HGEN) is 9.20 times as on 07-Mar-2024, a 64 premium to its peers’ median range of 5.60 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2022
|
-0.10
|
-0.15
|
|
2021
|
-0.98
|
-9.92
|
|
2020
|
-9.96
|
19.88
|
|
2019
|
-0.95
|
-0.77
|
|
2018
|
-1.28
|
-1.90
|
The 52-week high and low of Humanigen Inc (HGEN) are Rs -- and Rs -- as of 27-Apr-2026.
Humanigen Inc (HGEN) has a market capitalisation of $ 0 Mln as on 07-Mar-2024. As per SEBI classification, it is a Small Cap company.
Before investing in Humanigen Inc (HGEN), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.